living
immunotherapies 

We are empowering T cells to effectively fight cancer. 

Immunotherapies show great promise to revolutionize cancer treatment. Therefore, we put living T cells - key players in the immune system - at the center of our technology platforms. We are striving to create breakthrough therapies to fundamentally improve the lives of cancer patients.

Latest News

Medigene submits CTA for its first clinical trial with proprietary TCR cellular immunotherapy MDG1011

SHOW RELEASE

Medigene announces participation at further national and international conferences

SHOW RELEASE

Medigene and academic partners publish a method to enhance adoptive T-cell therapies

SHOW RELEASE

Fighting cancer with cutting-edge technologies

The therapeutic potential of human T cells can radically change the future of cancer treatment. Medigene uses its proprietary platform technologies to modify T cells for the fight against tumor cells, thereby activating the body’s own immune defense mechanisms.

TCRs

Generating large numbers of cancer-specific T cells to recognize and kill cancer cells. 

MORE ABOUT TCRs

DCS

An entirely new generation of DC vaccines being developed.

MORE ABOUT DCS

TABs

Developing monoclonal antibodies to recognize T cells.

MORE ABOUT TABS

Deeply rooted in Science

Our deep scientific expertise is rooted in decades of immunological research by Prof. Dr. Dolores J. Schendel and her team.

More about our expertise

Capacity to innovate

The cumulated scientific knowledge and experience of our scientists, allied with high-throughput automation technologies, accelerate the discovery and development process for new therapies.

MORE ABOUT OUR INNOVATIONs

Growing pipeline

Our growing pipeline of immunotherapy projects has its focus on bringing more and more natural TCRs into clinical development, augmenting proprietary clinical-stage DC vaccines.

More about our Pipeline

Nimble and efficient

At Medigene, we combine state-of-the-art science and an entrepreneurial start-up culture within the structures of an established biopharmaceutical company. 

MORE ABOUT OUR COMPANY

MDG1

Listed on the Frankfurt Stock Exchange, TecDAX, WKN: A1X3W

> 90

Headquartered in Munich, Germany, US offices in Washington, DC and San Diego, actually over 90 employees

+83%

Increase in Research & Development expenses for immunotherapies in Q1 2017

Partner-like

Medigene has developed several clinical stage drugs, ranging from the research phase to commercialization and product launch onto the market. In cooperation with partners, we intend to become a global leader in the field of T cell immunotherapies.

MORE ABOUT OUR PARTNERS

“We are delighted that Medigene can continue to grow on the basis of our scientific and commercial development and will expand its TCR technology platform.”
Dolores Schendel, CEO

Living immuno­therapies, together

Our highly qualified scientists are dedicated to working at the forefront of cancer immunotherapies. Working closely with our experienced business specialists, they jointly develop highly innovative and effective therapies in order to help patients with severe illnesses.

More about career